Nosebleed in Levolet - how severe and when it was recovered? (a real world drug study)

Summary:

We study how severe was Nosebleed, when it was recovered, drug effectiveness, race, and more among people who take Levolet (levothyroxine sodium). This phase IV clinical study is created by eHealthMe based on reports submitted to eHealthMe, and is updated regularly.

What is Levolet?

Levolet has active ingredients of levothyroxine sodium. eHealthMe is studying from 108 Levolet users. Check the latest studies of Levolet.

What is Nosebleed?

Nosebleed (bleeding from nose) is found to be associated with 2,078 drugs and 3,093 conditions by eHealthMe. Check the latest studies of Nosebleed.

On Aug, 02, 2026

45 people who have Nosebleed while taking Levolet were studied.

Severity of Nosebleed *:

least: 17.5 %
moderate: 50.0 %
severe: 30.0 %
most severe: 2.5 %

When people recovered from Nosebleed *:

while on drug: 10.34 %
after off the drug: 6.9 %
not yet: 82.76 %

Effectiveness of Levolet *:

not at all: 0.0 %
somewhat: 6.25 %
moderate: 21.88 %
high: 40.62 %
very high: 31.25 %

Race of the people *:

African American, Non-Hispanic: 2.7 %
American Indian/Alaska Native: 0.0 %
Asian: 2.7 %
Hispanic: 5.41 %
Native Hawaiians/Pacific Islanders: 0.0 %
Two or more races: 2.7 %
White, Non-Hispanic: 86.49 %

Time on Levolet *:

Gender of people when taking Levolet *:

female: 75.56 %
male: 24.44 %

Age of people when taking Levolet *:

Conditions people have *:

Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 27 people, 60.00%
High Blood Pressure: 13 people, 28.89%
High Blood Cholesterol: 12 people, 26.67%
Thyroid Diseases: 6 people, 13.33%
Migraine (headache): 6 people, 13.33%
Attention Deficit Hyperactivity Disorder (a chronic condition including attention difficulty, hyperactivity, and impulsiveness): 5 people, 11.11%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 5 people, 11.11%
Depression: 5 people, 11.11%
Chronic Thyroiditis (long lasting inflammation of thyroid gland): 4 people, 8.89%
Stress And Anxiety: 3 people, 6.67%

Other drugs people take besides Levolet *:

Lamictal: 3 people, 6.67%
Vitamin D: 3 people, 6.67%
Aspirin: 3 people, 6.67%
Famotidine: 3 people, 6.67%
Atorvastatin Calcium: 3 people, 6.67%
Fish Oil: 2 people, 4.44%
Multivitamin: 2 people, 4.44%
Ditropan: 2 people, 4.44%
Duloxetine Hydrochloride: 2 people, 4.44%
Restasis: 2 people, 4.44%

Other side effects people have besides Nosebleed *:

Nausea (feeling of having an urge to vomit): 3 people, 6.67%
Headache (pain in head): 3 people, 6.67%
Weakness: 2 people, 4.44%
Joint Pain: 2 people, 4.44%
Fatigue (feeling of tiredness): 2 people, 4.44%
Dry Mouth: 2 people, 4.44%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 2.22%
Foot, Leg, And Ankle Swelling: 1 person, 2.22%
Dry Skin: 1 person, 2.22%
Dry Eyes (lack of adequate tears): 1 person, 2.22%

* Approximation only. Some reports may have incomplete information.

Do you take Levolet and have Nosebleed?

Check whether Nosebleed is associated with a drug or a condition

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Related studies

Nosebleed in Levolet

How the study uses the data?

The study is based on levothyroxine sodium (the active ingredients of Levolet). Other drugs that have the same active ingredients (e.g. generic drugs) are considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.